Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
63
Recruiting, any sponsor type, condition "tuberculosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed506
63 trials
Showing 1 to 25, recently updated first.
- A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without LevofloxacinPivotal-lookingRecruiting
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT07947056 · 2,500 participants (planned) · Start Jun 6, 2026 · Primary completion Dec 2028
Drug: Standard 6-month treatment regimen; High dose Rifampicin (25mg/Kg) and 2 more · For: Tuberculosis, Pulmonary, Drug Sensitive
Sites: Guntur, India; Guwahati, India; Rajkot, India · 15 sites in all
- Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous MeningitisPivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05383742 · 330 participants (planned) · Start Dec 7, 2023 · Primary completion Oct 1, 2029
Drug: Rifampicin (RIF); Isoniazid (INH) and 5 more · For: Tuberculous Meningitis
Sites: Porto Alegre, Brazil; Rio de Janeiro, Brazil; Pune, India · 18 sites in all
- Shortened Regimen for Drug-susceptible TB in ChildrenPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06253715 · 860 participants (planned) · Start Jan 15, 2025 · Primary completion Sep 30, 2027
Drug: Isoniazid; Rifampin and 4 more · For: Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node and 1 more
Sites: Chennai, India; Pune, India; Bandung, Indonesia · 9 sites in all
PT Bio FarmaIndustry
NCT07647107 · 60 participants (planned) · Start Sep 8, 2026 · Primary completion Jul 2027
Drug: LipovaxinS4-EAH (Middle Dose); LipovaksinS4-EAH (High Dose) and 1 more · For: Tuberculosis; TB Infection
Sites: Jakarta Pusat, Indonesia
University of PennsylvaniaAcademic, hospital or other
NCT07830771 · 10 participants (planned) · Start Sep 22, 2026 · Primary completion Sep 30, 2028
Drug: [18F]-FAPI-74 · For: Tuberculosis, Pulmonary
Sites: Philadelphia, Pennsylvania
- Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary DiseasePivotal-lookingRecruiting
Bin CaoAcademic, hospital or other
NCT07213765 · 188 participants (planned) · Start Jul 24, 2025 · Primary completion Sep 30, 2028
Drug: Contezolid; Azithromycin and 5 more · For: Mycobacterium Avium Complex Pulmonary Disease
Sites: Hefei, China; Beijing, China; Guangzhou, China · 6 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07124559 · 144 participants (planned) · Start Sep 28, 2026 · Primary completion Jun 26, 2028
Drug: Rifapentine; Isoniazid and 1 more · For: Tuberculosis
Sites: Gaborone, Botswana; Molepolole, Botswana; Port-au-Prince, Haiti · 11 sites in all
- Evaluating the Safety and Immunogenicity of MTBVACPivotal-lookingRecruiting
HIV Vaccine Trials NetworkResearch network
NCT05947890 · 276 participants (planned) · Start Jan 30, 2024 · Primary completion Nov 2027
Drug: MTBVAC; BCG · For: HIV I Infection; Tuberculosis
Sites: Johannesburg, South Africa; Westdene, South Africa; Durban, South Africa · 16 sites in all
- Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)Pivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07163143 · 784 participants (planned) · Start Oct 12, 2026 · Primary completion Nov 2028
Drug: Isoniazid (H); Rifampicin (R) and 2 more · For: Tuberculosis (TB)
Sites: Islamabad, Pakistan; Johannesburg, South Africa; Bulawayo, Zimbabwe · 4 sites in all
Huashan HospitalAcademic, hospital or other
NCT07893444 · 90 participants (planned) · Start Jul 8, 2026 · Primary completion Nov 30, 2027
Drug: 4-month FDC-based regimen; 3-month BDCZ regimen and 1 more · For: Tuberculosis
Sites: Fuzhou, China; Guangzhou, China; Guiyang, China · 13 sites in all
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisPivotal-lookingRecruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07209761 · 532 participants (planned) · Start Oct 16, 2025 · Primary completion Sep 29, 2028
Drug: Bedaquiline; Quabodepistat and 3 more · For: Rifampicin-Resistant Pulmonary Tuberculosis; Multidrug-Resistant Pulmonary Tuberculosis
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 42 sites in all
Gates Medical Research InstituteAcademic, hospital or other
NCT07883226 · 66 participants (planned) · Start Oct 21, 2026 · Primary completion May 30, 2027
Drug: TBD11 (300 mg); Placebo and 4 more · For: Healthy Adult Participants
Sites: Bloemfontein, South Africa
- ID93/GLA-SE Vaccination + BCG ChallengeRecruiting
University of OxfordAcademic, hospital or other
NCT06670755 · 48 participants (planned) · Start Dec 18, 2024 · Primary completion Jul 31, 2027
Drug: ID93/GLA-SE; BCG Danish · For: Tuberculosis
Sites: Oxford, United Kingdom
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TBPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06568484 · 2,530 participants (planned) · Start May 8, 2026 · Primary completion Jul 2027
Drug: Bedaquiline; Levofloxacin · For: Tuberculosis, Latent
Sites: Ulaanbaatar, Mongolia; Lima, Peru; Mbeya, Tanzania · 8 sites in all
- BPaLMZ for TB MeningitisPivotal-lookingRecruiting
David BoulwareAcademic, hospital or other
NCT07227779 · 312 participants (planned) · Start Jul 28, 2026 · Primary completion Mar 31, 2028
Drug: BPaLMZ Regimen · For: Tuberculous Meningitis; HIV; Meningitis and 1 more
Sites: Kampala, Uganda; Mbarara, Uganda
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07784894 · 28 participants (planned) · Start Aug 20, 2026 · Primary completion Nov 17, 2026
Drug: Ganfeborole; Microgynon · For: Tuberculosis
Sites: Madrid, Spain
- Prevention of Ototoxicity in NTM Patients Treated With IV AmikacinPivotal-lookingRecruiting
Kevin WinthropAcademic, hospital or other
NCT05730283 · 105 participants (planned) · Start Jun 2, 2025 · Primary completion Feb 29, 2028
Drug: ORC-13661; ORC-13661 and 1 more · For: Ototoxicity, Drug-Induced
Sites: San Francisco, California; Denver, Colorado; Baltimore, Maryland · 8 sites in all
- Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)Pivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT07486024 · 55 participants (planned) · Start Sep 11, 2026 · Primary completion Aug 2030
Drug: Bedaquiline Oral Tablet; Bedaquiline Oral Tablet · For: MDR-TB; Tuberculosis Multi Drug Resistant Active; Antibiotic Resistance and 1 more
Sites: Amiens, France; Paris, France; Rennes, France · 5 sites in all
- rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderPivotal-lookingRecruiting
Biothervax SpAIndustry
NCT07762014 · 200 participants (planned) · Start Sep 14, 2026 · Primary completion Sep 7, 2027
Drug: Vaccination with rBCG-N-RSV; Vaccination with conventional BCG (BCG-WT) · For: Respiratory Syncytial Virus Infection Prevention; Tuberculosis Prevention
Sites: Athens, Greece
- Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB TreatmentPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06497465 · 150 participants (planned) · Start Sep 18, 2025 · Primary completion Jan 31, 2028
Drug: Dolutegravir 50mg Tab; Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO] and 1 more · For: Tuberculosis; HIV
Sites: Manaus, Brazil; Salvador, Brazil; Rio de Janeiro, Brazil · 5 sites in all
Affiliated Hospital of Nantong UniversityAcademic, hospital or other
NCT07811518 · 3,000 participants (planned) · Start Aug 15, 2022 · Primary completion Aug 31, 2026
Drug: tuberculosis preventive treatment · For: Latent Tuberculosis Infection (LTBI); Tuberculosis (TB)
Sites: Nantong, China; Meishan, China
- Program for Rifampicin-Resistant Disease With Stratified Medicine for TuberculosisPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06441006 · 400 participants (planned) · Start Oct 3, 2025 · Primary completion Aug 2031
Drug: Bedaquiline; Linezolid and 3 more · For: Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
Sites: Ulaanbaatar, Mongolia; Kotri, Pakistan; Lima, Peru · 6 sites in all
- Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TBPivotal-lookingRecruiting
Global Alliance for TB Drug DevelopmentAcademic, hospital or other
NCT07672405 · 100 participants (planned) · Start Jul 9, 2026 · Primary completion May 28, 2027
Drug: sorfequiline; Pretomanid and 1 more · For: Tuberculosis, Pulmonary
Sites: Wentworth, South Africa; Port Elizabeth, South Africa; Soshanguve, South Africa · 12 sites in all
- Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, TrialPivotal-lookingRecruiting
Kaohsiung Veterans General Hospital.Academic, hospital or other
NCT06727864 · 270 participants (planned) · Start Jan 1, 2024 · Primary completion Dec 31, 2027
Drug: 4-month regimen (2HERZ/2HRE); 6-month (2HERZ/4HRE) · For: Pulmonary Tuberculosis
Sites: New Taipei City, Taiwan; Taichung, Taiwan; Kaohsiung City, Taiwan · 8 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.